![]() ![]() NSABP Members' Area Password Protected - Access Limited to NSABP Participating Institutions Only NSABP Foundation, Inc. General NSABP Information Financial Conflicts of Interest Policy Contact the NSABP Employment ![]() Clinical Trials Information Clinical Trials Overview Protocol Chart Never Say Lost Treatment Trials Information Protocol B-51 Protocol B-52 Protocol B-53/S1207 Protocol B-55/BIG 6-13 Prevention Trials Information Protocol P-1 - BCPT Protocol P-2 - STAR To report problems, ask questions or make comments, please send e-mail to: Webmaster@nsabp.pitt.edu |
Protocol B-12 A Protocol to Compare L-PAM, 5-FU and Tamoxifen With and Without Adriamycin in the Management of Primary Breast Cancer Patients With Positive Axillary Nodes Whose Tumors are Positive for Estrogen and/or Progesterone Receptors Specific Aims To determine whether L-PAM + Adriamycin + 5-FU + tamoxifen (PAFT) is more effective than L-PAM + 5-FU + tamoxifen (PFT) in disease-free survival and survival of patients with one or more positive nodes whose tumors are estrogen-receptor (ER) positive and/or progesterone-receptor (PR) positive. ![]() |